Cargando…
INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease
OBJECTIVE: To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk. METHODS: Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year d...
Autores principales: | Meyer, Pierre-François, Tremblay-Mercier, Jennifer, Leoutsakos, Jeannie, Madjar, Cécile, Lafaille-Maignan, Marie-Élyse, Savard, Melissa, Rosa-Neto, Pedro, Poirier, Judes, Etienne, Pierre, Breitner, John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512884/ https://www.ncbi.nlm.nih.gov/pubmed/30952794 http://dx.doi.org/10.1212/WNL.0000000000007232 |
Ejemplares similares
-
Lymphocytes Are Not Required for Neurogenic Heterotopic Ossification Development after Spinal Cord Injury
por: Alexander, Kylie A., et al.
Publicado: (2022) -
Repetitive TMS does not improve cognition in patients with TBI: A randomized double-blind trial
por: Neville, Iuri Santana, et al.
Publicado: (2019) -
A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy
por: Lochmüller, Hanns, et al.
Publicado: (2019) -
In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020) -
Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies
por: Todd, Joshua J., et al.
Publicado: (2020)